SBIO Holdings
104 holdings in the fund's latest file; the data source updated it on Oct 8, 2026.
Top 25 Holdings
| # | Holding | Weight | Shares (as reported) | Value (as reported) |
|---|---|---|---|---|
| 1 | CG oncology Inc. | 3.73% | 112,596 | $7.0M |
| 2 | Oruka Therapeutics Inc. | 3.55% | 84,115 | $6.7M |
| 3 | Travere Therapeutics Inc. | 3.40% | 119,727 | $6.4M |
| 4 | Dianthus Therapeutics Inc. | 3.20% | 71,016 | $6.0M |
| 5 | Definium Therapeutics Inc. | 3.18% | 170,644 | $6.0M |
| 6 | VeraDermics Inc. | 3.13% | 53,064 | $5.9M |
| 7 | Edgewise Therapeutics Inc. | 2.90% | 137,912 | $5.5M |
| 8 | Relay Therapeutics Inc. | 2.65% | 278,309 | $5.0M |
| 9 | Xenon Pharmaceuticals Inc. | 2.38% | 122,979 | $4.5M |
| 10 | Ideaya Biosciences Inc. | 2.36% | 122,543 | $4.4M |
| 11 | Amylyx Pharmaceuticals Inc. | 2.32% | 159,427 | $4.4M |
| 12 | ACADIA Pharmaceuticals Inc. | 2.28% | 218,864 | $4.3M |
| 13 | Tarsus Pharmaceuticals Inc. | 2.18% | 55,724 | $4.1M |
| 14 | Denali Therapeutics Inc. | 2.07% | 203,012 | $3.9M |
| 15 | Dyne Therapeutics Inc. | 2.01% | 237,167 | $3.8M |
| 16 | Zai Lab Ltd. | 1.92% | 142,831 | $3.6M |
| 17 | Newamsterdam Pharma Co. NV (NAMS) | 1.78% | 151,846 | $3.4M |
| 18 | MBX Biosciences Inc. | 1.77% | 61,160 | $3.3M |
| 19 | Celldex Therapeutics Inc. | 1.61% | 99,752 | $3.0M |
| 20 | Disc Medicine Inc. | 1.58% | 48,750 | $3.0M |
| 21 | SELLAS Life Sciences Group Inc. | 1.54% | 256,475 | $2.9M |
| 22 | Vera Therapeutics Inc. | 1.47% | 91,547 | $2.8M |
| 23 | Immunome Inc. | 1.46% | 144,280 | $2.8M |
| 24 | BioCryst Pharmaceuticals Inc. | 1.45% | 324,541 | $2.7M |
| 25 | Vericel Corp. | 1.41% | 65,052 | $2.7M |
Sector Weights
- Healthcare: 100.00%
Country Weights
- United States: 88.92%
- Canada: 2.38%
- United Kingdom: 2.24%
- China: 1.92%
- Netherlands: 1.78%
- Belgium: 1.64%
- Germany: 0.75%
- Switzerland: 0.35%
- Other: 0.01%
Shares, value and weight are as reported in the file, dated by the data source's last update of it (not the date of the positions), never adjusted; a split warning appears only for a split close to or after that date, and its absence does not mean the count is on today's share basis. Weights as the fund reports them. Leveraged and inverse funds list swaps and cash, so weights can be negative or add up past 100.